SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 8.76% Stake in Supernus Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.76% in Supernus Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as 'Reporting Persons,' have filed an Amendment No. 6 to Schedule 13G regarding their beneficial ownership in Supernus Pharmaceuticals, Inc.
• The filing reports beneficial ownership of 4,836,000 shares of Common Stock in Supernus Pharmaceuticals, Inc.
• This represents 8.76% of the outstanding Common Stock of Supernus Pharmaceuticals, Inc.
• The percentage of shares beneficially owned is based on 55,219,273 shares outstanding as of October 30, 2024, as reported in Supernus Pharmaceuticals, Inc.'s Form 10-Q filed with the SEC on November 4, 2024.
• Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the reported shares.
• Steven Boyd is identified as the managing member of Armistice Capital, LLC.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

NA

Related Party Transactions

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd is the managing member of Armistice Capital, LLC, establishing a relationship between the reporting persons and the direct holder of the securities.

Stakeholder Impact

• Shareholders: The disclosure of a significant ownership stake by an investment firm provides transparency regarding the company's ownership structure and may influence investor perception.

Key Dates

Keywords

Supernus Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management